| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gary Remington, Ofer Agid, George Foussias, Margaret Hahn, Naren Rao, Mark Sinyo. Clozapine's role in the treatment of first-episode schizophrenia. The American journal of psychiatry. vol 170. issue 2. 2013-03-25. PMID:23377634. |
in contrast, the notable reduction in response rate to second-line treatments, coupled with clozapine's substantial response rate in refractory schizophrenia and evidence indicating better outcomes with early, effective treatment, makes a compelling argument for research examining clinical and functional outcomes with clozapine positioned as a second-line treatment. |
2013-03-25 |
2023-08-12 |
Not clear |
| Jimmi Nielsen, Rasmus Røge, Ole Schjerning, Holger J Sørensen, David Taylo. Geographical and temporal variations in clozapine prescription for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 11. 2013-03-18. PMID:22503785. |
geographical and temporal variations in clozapine prescription for schizophrenia. |
2013-03-18 |
2023-08-12 |
Not clear |
| Jimmi Nielsen, Rasmus Røge, Ole Schjerning, Holger J Sørensen, David Taylo. Geographical and temporal variations in clozapine prescription for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 11. 2013-03-18. PMID:22503785. |
trends in the prescription of clozapine in patients with icd-10 f20.x schizophrenia were assessed using data from danish national registers. |
2013-03-18 |
2023-08-12 |
Not clear |
| Jimmi Nielsen, Rasmus Røge, Ole Schjerning, Holger J Sørensen, David Taylo. Geographical and temporal variations in clozapine prescription for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 11. 2013-03-18. PMID:22503785. |
three substudies were carried out: (i) an assessment of differences in national prescription patterns between 1996 and 2007 using a cross-sectional design; (ii) a comparison of time from first schizophrenia diagnosis to first prescription of clozapine in a five-year cohort study, using the cox regression model, of two patient groups who were first diagnosed in 1996 and in 2003; (iii) an assessment of differences in the general psychiatric hospitals' use of clozapine in 2009. |
2013-03-18 |
2023-08-12 |
Not clear |
| Jimmi Nielsen, Rasmus Røge, Ole Schjerning, Holger J Sørensen, David Taylo. Geographical and temporal variations in clozapine prescription for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 11. 2013-03-18. PMID:22503785. |
the results are as follows: (i) the percentage of schizophrenia patients receiving clozapine rose from 9.0% in 1996 to 10.1% in 2007 (p<0.001). |
2013-03-18 |
2023-08-12 |
Not clear |
| Jimmi Nielsen, Rasmus Røge, Ole Schjerning, Holger J Sørensen, David Taylo. Geographical and temporal variations in clozapine prescription for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 11. 2013-03-18. PMID:22503785. |
(ii) time from diagnosis with schizophrenia until first clozapine prescription was longer for patients diagnosed in 2003 compared to those diagnosed in 1996 (hr: 0.28 ci: 0.16-0.49). |
2013-03-18 |
2023-08-12 |
Not clear |
| Jimmi Nielsen, Rasmus Røge, Ole Schjerning, Holger J Sørensen, David Taylo. Geographical and temporal variations in clozapine prescription for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 11. 2013-03-18. PMID:22503785. |
although, the percentage of schizophrenia patients receiving clozapine increased from 1996 to 2007, the time from diagnosis of schizophrenia until first prescription of clozapine increased. |
2013-03-18 |
2023-08-12 |
Not clear |
| Tian-Mei Si, Yun-Shu Zhang, Liang Shu, Ke-Qing Li, Xie-He Liu, Qi-Yi Mei, Gao-Hua Wang, Pei-Shen Bai, Li-Ping Ji, Xian-Sheng Cheng, Cui Ma, Jian-Guo Shi, Hong-Yan Zhang, Hong Ma, Xin Y. Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studies. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 10. issue 2. 2013-02-25. PMID:23430459. |
use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studies. |
2013-02-25 |
2023-08-12 |
Not clear |
| b' Kazuhiro Tajima-Pozo, Diana Zambrano-Enriquez, Laura de Anta, Mar\\xc3\\xada Dolores Moron, Jose Luis Carrasco, Juan Jos\\xc3\\xa9 Lopez-Ibor, Marina Diaz-Mars\\xc3\\xa. Practicing exorcism in schizophrenia. BMJ case reports. vol 2011. 2013-02-19. PMID:22707465.' |
we report the case of a 28-year-old patient who had been diagnosed 5 years previously with paranoid schizophrenia (treated with clozapine, risperidone, ziprasidone and onlanzapine without a complete response) and was also receiving treatment in a first episode psychosis unit in spain. |
2013-02-19 |
2023-08-12 |
Not clear |
| Albertine A Scheltema Beduin, Marije Swets, Marise Machielsen, Nikie Korve. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. The Journal of clinical psychiatry. vol 73. issue 11. 2013-02-19. PMID:23218156. |
obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. |
2013-02-19 |
2023-08-12 |
Not clear |
| Albertine A Scheltema Beduin, Marije Swets, Marise Machielsen, Nikie Korve. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. The Journal of clinical psychiatry. vol 73. issue 11. 2013-02-19. PMID:23218156. |
to compare the prevalence of obsessive-compulsive symptoms (ocs) in a population of patients with schizophrenia taking clozapine, olanzapine, or risperidone or taking no antipsychotic medication. |
2013-02-19 |
2023-08-12 |
Not clear |
| Thomas I F H Cremers, Gunnar Flik, Corry Hofland, Robert E Stratfor. Microdialysis evaluation of clozapine and N-desmethylclozapine pharmacokinetics in rat brain. Drug metabolism and disposition: the biological fate of chemicals. vol 40. issue 10. 2013-02-14. PMID:22736307. |
a significant barrier to realization of the full potential of clozapine as a therapeutic agent in the treatment of schizophrenia is the substantial interpatient variability that exists along the therapeutic continuum of no response-efficacious response-adverse response. |
2013-02-14 |
2023-08-12 |
human |
| Thomas I F H Cremers, Gunnar Flik, Corry Hofland, Robert E Stratfor. Microdialysis evaluation of clozapine and N-desmethylclozapine pharmacokinetics in rat brain. Drug metabolism and disposition: the biological fate of chemicals. vol 40. issue 10. 2013-02-14. PMID:22736307. |
the results obtained with clozapine and n-desmethylclozapine are considered a first step in the development of preclinical pharmacokinetic-pharmacodynamic models that will support deeper mechanistic studies of clozapine in in vivo pharmacology, as well as the development of translational models that augment pharmacogenetic investigations that seek to improve the safety and efficacy of clozapine therapeutic intervention in the treatment of schizophrenia. |
2013-02-14 |
2023-08-12 |
human |
| Marco Innamorati, Stefano Baratta, Cristina Di Vittorio, David Lester, Paolo Girardi, Maurizio Pompili, Mario Amor. Atypical antipsychotics in the treatment of depressive and psychotic symptoms in patients with chronic schizophrenia: a naturalistic study. Schizophrenia research and treatment. vol 2013. 2013-02-13. PMID:23401771. |
the aim of this naturalistic study was to investigate whether treatment with clozapine and other atypical antipsychotics for at least 2 years was associated with a reduction in psychotic and depressive symptoms and an improvement in chronic schizophrenia patients' awareness of their illness. |
2013-02-13 |
2023-08-12 |
Not clear |
| Jaskanwal Sara, Matt Jenkins, Tanveer Chohan, Karan Jolly, Lisa Shepherd, Nirav Y Gandhi, Jayadave Shakhe. Clozapine use presenting with pseudopheochromocytoma in a schizophrenic patient: a case report. Case reports in endocrinology. vol 2013. 2013-02-13. PMID:23401805. |
the patient had underlying schizophrenia and was stable on clozapine. |
2013-02-13 |
2023-08-12 |
Not clear |
| István Gacsályi, Katalin Nagy, Katalin Pallagi, György Lévay, László G Hársing, Krisztina Móricz, Szabolcs Kertész, Péter Varga, József Haller, Gábor Gigler, Gábor Szénási, József Barkóczy, Judit Bíró, Michael Spedding, Ferenc A Anton. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology. vol 64. 2013-02-11. PMID:22824189. |
the introduction of atypical antipsychotics such as risperidone, olanzapine and clozapine has obviated this problem, but none of the current drugs seem to improve the cognitive deficits accompanying schizophrenia. |
2013-02-11 |
2023-08-12 |
mouse |
| Anatoly A Mazurov, David C Kombo, Terry A Hauser, Lan Miao, Gary Dull, John F Genus, Nikolai B Fedorov, Lisa Benson, Serguei Sidach, Yunde Xiao, Philip S Hammond, John W James, Craig H Miller, Daniel Yohanne. Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders. Journal of medicinal chemistry. vol 55. issue 22. 2013-02-05. PMID:23126648. |
7a had positive effects across cognitive, positive, and negative symptoms of schizophrenia in animal models and was additive or synergistic with the antipsychotic clozapine. |
2013-02-05 |
2023-08-12 |
Not clear |
| Iris E Sommer, Marieke J H Begemann, Anke Temmerman, Stefan Leuch. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia bulletin. vol 38. issue 5. 2013-02-04. PMID:21422107. |
pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. |
2013-02-04 |
2023-08-12 |
Not clear |
| Iris E Sommer, Marieke J H Begemann, Anke Temmerman, Stefan Leuch. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia bulletin. vol 38. issue 5. 2013-02-04. PMID:21422107. |
when schizophrenia patients have insufficient response to clozapine, pharmacological augmentation is often applied. |
2013-02-04 |
2023-08-12 |
Not clear |
| Hyung-Wook Kim, Yewon Cheon, Hiren R Modi, Stanley I Rapoport, Jagadeesh S Ra. Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain. Psychopharmacology. vol 222. issue 4. 2013-01-22. PMID:22414961. |
the mode of action of clozapine, an atypical antipsychotic approved for treating schizophrenia (sz) and used for bipolar disorder (bd) mania, remains unclear. |
2013-01-22 |
2023-08-12 |
rat |